Search

everythinglearnresearchcommunity

for

Search:↓

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Tofacitinib taken by mouth helps treat hair loss in children.

A new test helps find drugs to treat head and neck cancer by targeting c-Rel.

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

c-Kit is important for heart regeneration and cancer development.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Tadalafil and Finasteride may help treat aggressive melanoma.

Sorafenib often causes skin side effects, indicating effective cancer treatment.

The FDA approved a new Pfizer drug for hair loss in teens.

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Cancer cells often have more copies of TERT and TERC genes, which helps them grow and could affect patient outcomes.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

EGFR-TKIs can cause unexpected skin, nail, and hair issues.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Cialis and Finasteride could be repurposed to treat aggressive melanoma.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.